{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-059659","form_type":"8-K","ticker":"NVAX","cik":"0001000694","company_name":"NOVAVAX INC","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.782981+00:00","generated_at":"2026-06-02T03:08:59.414533+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Novavax signs $1.3B Sanofi deal; Q1 revenue $94M, net loss $148M; removes going concern","bullets":["Co-exclusive licensing with Sanofi includes $500M upfront, ~$70M equity, up to $700M milestones plus royalties per product.","Q1 2024 revenue $94M (up from $81M YoY), net loss $148M (improved from $294M loss YoY).","Reduced current liabilities by $831M in Q1; removed going concern notice.","Updated 2024 guidance: Combined Revenue & Sanofi Payments $970M-$1,170M; Total Revenue $400M-$600M.","Added standalone influenza arm to Phase 3 COVID-Flu combo trial; on track for H2 2024 initiation, potential 2026 launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-059659","json":"https://secwatch.observer/filing/0001104659-24-059659.json","markdown":"https://secwatch.observer/filing/0001104659-24-059659.md","text":"https://secwatch.observer/filing/0001104659-24-059659.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924059659/0001104659-24-059659-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924059659/tm2414089d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:08:59.414533+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9dcb71a47f6de8f1916217aa80490f57e7d35c02","claim":"NOVAVAX INC reported the first quarter ended March 31, 2024 results: revenue $94 million.","evidence_excerpt":"half of 2024, with potential 2026 launch for both candidates · Reduced current liabilities by an additional $831 million during Q1 2024 · Achieved total revenue in Q1 2024 of $94 million · Novavax removes going concern notice · Company to host conference call today at 8:30 a.m. ET GAITHERSBURG, Md., May 10, 2024 – Novavax, Inc. (Nasdaq: NVAX), a global company","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1000694/000110465924059659/0001104659-24-059659-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$94 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}